Oblique Therapeutics is a curiosity-driven, innovative biotech company with strong scientific acumen and drive for increasing the bandwidth of antibody therapeutics for the benefit of patients.

We have a solid portfolio of promising future medicines and proprietary AbiprotTM technology, our evergreen antibody platform that can generate functional antibodies to any given disease-modifying target.

We are focusing on finding new treatment paradigms for severe diseases such as advanced cancer and pain. We also work on two type 2 diabetes programs through a major pharma collaboration.

Recent news

01 Nov 2018


Our CEO, Owe Orwar, and CSO, Carolina Trkulja, will be attending BioEurope in Copenhagen, 5-7 November, 2018